IceCure Medical ends VP Operations contract, effective Jan 15, 2026

IceCure Medical reported an executive change, delivering a notice of termination to Vice President of Operations and Services Galit Malik, with her employment ending on January 15, 2026.

Rhea-AI Filing Summary

IceCure Medical reported an executive change, delivering a notice of termination to Vice President of Operations and Services Galit Malik, with her employment ending on January 15, 2026. The company stated the termination was not related to any disagreement regarding operations, policies, or practices.

The report is furnished on Form 6-K and is incorporated by reference into IceCure Medical’s existing Form F-3 and Form S-8 registration statements.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What executive change did ICCM announce?

IceCure Medical delivered a notice of termination to Vice President of Operations and Services Galit Malik.

When does Galit Malik’s termination become effective at ICCM?

Her employment contract will be terminated as of January 15, 2026.

Did the termination involve any disagreement at ICCM?

The company stated it was not related to any disagreement on operations, policies, or practices.

What filing format was used for this update by ICCM?

The update was furnished on Form 6-K.

Are any registration statements affected by this ICCM 6-K?

Yes. The 6-K is incorporated by reference into the company’s Form F-3 and Form S-8 registration statements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/17/2025 - 12:00 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of: October 2025 (Report No. 2)

Commission File Number: 001-40753

ICECURE MEDICAL LTD.

(Translation of registrant’s name into English)

7 Ha’Eshel St., PO Box 3163

Caesarea, 3079504 Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F             ☐ Form 40-F

CONTENTS

On October 16, 2025, IceCure Medical Ltd. (the “Company”) delivered a notice of termination to Ms. Galit Malik, the Company’s Vice President of Operations and Services, notifying Ms. Malik that her employment contract will be terminated as of January 15, 2026. Ms. Malik’s termination was not related to any disagreement with the Company on any matter relating to its operations, policies or practices.

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (Registration Nos. 333-258660, 333-267272 and 333-290046) and Form S-8 (Registration Nos. 333-270982, 333-264578, 333-262620 and 333-281587), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ICECURE MEDICAL LTD.
Date: October 17, 2025	By:	/s/ Eyal Shamir
		Name:	Eyal Shamir
		Title:	Chief Executive Officer

2